Compare Regeneron Pharmaceuticals Inc (REGN) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Wix.Com Ltd — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Wix.Com Ltd trades at $49.99 (market cap $2.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 33.1× Wix.Com Ltd's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals.
| REGN | WIX | |
|---|---|---|
Market Cap | $70.79B | $2.14B |
Sector | Health | Technology |
52-Week High | $812.27 | $184.24 |
52-Week Low | $545.46 | $40.43 |
Enterprise Value | $64.74B | $1.70B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Wix.com trades at $51.12, down 0.64% on the day, with a mixed technical outlook showing bullish moving averages but overbought RSI levels. Revenue growth remains strong, reaching $1.99B in 2025, though net income margin turned negative at -1.97%. Recent news includes product launches like Wix Headless AI integration and multiple law firm investigations into potential securities fraud following a 56% stock decline in H1 2026.
The stock presents a high-risk, high-reward profile with a consensus price target of $77.50 implying 52% upside, but faces headwinds from earnings volatility, negative equity, and legal scrutiny. Long-term growth drivers in AI and small business tools are countered by near-term execution risks and competitive pressures in the website-building space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
